

In the Specification:

At page 1, please delete the first paragraph of the specification (starting at line 3 and ending at line 20) and add the following replacement paragraph:

This application is a continuation of application Serial No. 09/135,202, filed August 17, 1998, which is a division of application Serial No. 08/471,973, filed on June 6, 1995 (now U.S. Patent No. 5,872,232) and a continuation-in-part of application Serial No. 08/465,880, filed on June 6, 1995 (now U.S. Patent No. 5,955,589). Application Serial No. 08/465,880 is a continuation-in-part of application Serial No. 08/244,993, filed on June 21, 1994 (now U.S. Patent No. 5,623,065), which is the U.S. national phase application of International application PCT/US92/11339, filed on December 23, 1992 (now abandoned), and is a continuation-in-part of application Serial No. 07/814,961, filed on December 24, 1991 (now abandoned). Application Serial No. 08/471,973, filed June 6, 1995, is a continuation-in-part of Application serial no. 07/835,932, filed March 5, 1992, which is a U.S. national phase application of International application Serial No. PCT/US91/05720, filed August 12, 1991, which is a PCT continuation-in-part of Application Serial No. 07/566,977, filed August 13, 1990 (now abandoned).

In the Claims

Please add claim 13 and insert claims 8 to 12 as presented below in amended form:

8 (Amended). A mixed sequence oligonucleotide or oligonucleotide analog including more than one 2'-modified 2'-deoxyfuranosyl moiety wherein said modification comprises substitution by halo, azido, amino, alkloxy, thioalkoxy, alkylamino, alkyl, and wherein one of

said 2'-modified 2'-deoxyfuranosyl moieties is different from another of said 2'-modified 2'-deoxyfuranosyl moieties.

a 2' comod
Sub D

9 (Amended). The mixed sequence oligonucleotide or oligonucleotide analog of claim 8, wherein one of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by halo, azido, amino, thioalkoxy, alkylamino or alkyl and another of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by alkyloxy.

10 (Amended). The mixed sequence oligonucleotide or oligonucleotide analog of claim 8, wherein one of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by halo, azido, amino, thioalkoxy or alkyl and another of said 2'-modified 2'-deoxyfuranosyl moieties comprises substitution by methoxy.

CB
Sub D

11 (Amended). The mixed sequence oligonucleotide or oligonucleotide analog of claim 8, wherein alkyl comprises a straight or branched chain alkyl.

CB
Sub D

12 (Amended). The mixed sequence oligonucleotide or oligonucleotide analog of claim 11, wherein alkyl includes unsaturation within the alkyl carbon chain.

CB
Sub D

13 (New) The mixed sequence oligonucleotide of claim 8 wherein said oligonucleotide is a nuclease resistant oligonucleotide.